Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study - Centre Daily Times PDF Print
Centre Daily Times
BOSTON — Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia™. Bendavia is a novel compound that

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.